The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which are related to the severity of the disease [170,171].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [171]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With Cas9, several research groups targeted this core region of HBV genome, both in vivo and in vitro, successfully supressing the virus with significant and long-lasting reductions in viral load and antigen production, which are related to the severity of the disease [170,171].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [171]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · cited 2×
“, 2014) were shown to effectively cleave and inactivate viral DNA in both HIV-1 and HPV-infected human cells (Ebina et al., 2013; Hu et al., 2014; Kennedy et al., 2014), and we therefore wished to test whether Cas9/sgRNA combinations specific for the HBV DNA genome might be able to also cleave and reduce HBV DNA level…”
Research works printed but not linked: 23
- Barrangou, 2014, CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity, Mol. Cell, 54, 234, 10.1016/j.molcel.2014.03.011 · DOI · Paper page
- Chen, 2004, HBV cccDNA in patients’ sera as an indicator for HBV reactivation and an early signal of liver damage, World J. Gastroenterol., 10, 82, 10.3748/wjg.v10.i1.82 · DOI
- Dandri, 2014, Mouse models of hepatitis B and delta virus infection, J. Immunol. Methods, 410C, 39, 10.1016/j.jim.2014.03.002 · DOI
- Esvelt, 2013, Orthogonal Cas9 proteins for RNA-guided gene regulation and editing, Nat. Methods, 10, 1116, 10.1038/nmeth.2681 · DOI · Paper page
- Gripon, 2002, Infection of a human hepatoma cell line by hepatitis B virus, Proc. Natl. Acad. Sci. U.S.A., 99, 15655, 10.1073/pnas.232137699 · DOI
- Hantz, 2009, Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells, J. Gen. Virol., 90, 127, 10.1099/vir.0.004861-0 · DOI
- Hsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell, 157, 1262, 10.1016/j.cell.2014.05.010 · DOI · Paper page
- Hu, 2014, RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection, Proc. Natl. Acad. Sci. U.S.A., 111, 11461, 10.1073/pnas.1405186111 · DOI · Paper page
- Kennedy, 2014, Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease, J. Virol., 88, 11965, 10.1128/JVI.01879-14 · DOI
- King, 2000, Hep AD38 Assay: a high-throughput, cell-based screen for the evaluation of compounds against hepatitis B virus, Methods Mol. Med., 24, 43
- Komatsu, 2014, Hepatitis B virus: where do we stand and what is the next step for eradication?, World J. Gastroenterol., 20, 8998
- Ladner, 1997, Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication, Antimicrob. Agents Chemother., 41, 1715, 10.1128/AAC.41.8.1715 · DOI
- Lin, 2014, The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates In Vivo, Mol. Ther. Nucleic Acids, 3, e186, 10.1038/mtna.2014.38 · DOI · Paper page
- Liu, 2004, Dynamic analysis of hepatitis B virus DNA and its antigens in 2.2.15 cells, J. Viral. Hepatitis, 11, 124, 10.1046/j.1365-2893.2003.00485.x · DOI
- Lucifora, 2014, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, 343, 1221, 10.1126/science.1243462 · DOI
- Malmstrom, 2012, Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load—down-regulated transcription of PgRNA has limited impact, PLoS One, 7, e36349, 10.1371/journal.pone.0036349 · DOI
- Pas, 2000, Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays, J. Clin. Microbiol., 38, 2897, 10.1128/JCM.38.8.2897-2901.2000 · DOI
- Sells, 1987, Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA, Proc. Natl. Acad. Sci. U.S.A., 84, 1005, 10.1073/pnas.84.4.1005 · DOI
- Stuyver, 2002, Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues, Antimicrob. Agents Chemother., 46, 3854, 10.1128/AAC.46.12.3854-3860.2002 · DOI
- Wang, 2014, Genetic screens in human cells using the CRISPR-Cas9 system, Science, 343, 80, 10.1126/science.1246981 · DOI · Paper page
- Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 · DOI · Paper page
- Yang, 2013, One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering, Cell, 154, 1370, 10.1016/j.cell.2013.08.022 · DOI · Paper page
- Zhou, 2014, High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells, Nature, 509, 487, 10.1038/nature13166 · DOI · Paper page
Cited by
Sorted by citations
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
Vijayraghavan, S., & Kantor, B. (2017) · Journal of Visualized Experiments · doi:10.3791/56915 · Cited by 20
Metadata
- Authors
- Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V. R., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F., & Cullen, B. R.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 476
- Pages
- 196-205
- ISSN
- 0042-6822
- PMC
- PMC4323668
- Cited by
- 209
- References
- 4
- Language
- en
- Licence
- Funders
- postdoctoral fellowship from Hofffmann-LaRoche
- Department of Veterans Affairs (RFS)
- NIH CFAR (P30-AI050409)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
